Turmeric Curcuma longa L. is a perennial herb of the genus Turmeric in the family Zingiberaceae, which produces a wide range of secondary metabolites, including substances such as flavonoids, alkaloids, tannins and phenolic acids. Curcumin is one of the most representative active substances, whichbulk curcumin pulver kan användas vid behandling av inflammatoriska sjukdomar, leversjukdomar, metaboliskt syndrom, neurodegenerativa sjukdomar, åderförkalkning och hjärtinfarkt . viktigast, curcumin har en terapeutisk effekt på ett brett utbud av tumörer som lunga, bröst, prostat och mage cancer {}}}}}}}}}}}}}}}}}}}
Bulk curcumin pulverwas first extracted from the turmeric plant in 1870. Since then, scientists have conducted many studies on the therapeutic effects of bulk turmeric curcumin as a non-toxic drug. Notably, it is classified as 'Generally Recognised as Safe' (GRAS) by the US National Cancer Institute.) The activity of curcumin as an anticancer agent has received much attention over the De senaste tre till fyra decennierna . prekliniska studier stöder curcumin som en lovande anticancerkandidat . Dessutom har dess anticancermekanismer avslöjats på många sätt . till exempel, det inducerar apoptos och hämmar tumörtillväxt och proliferation genom att exploatera i de mättnader av cellsignal)
• Anti-lungcancereffekter
Bulkcurcuminpulvershows its potential for the treatment of lung cancer by acting on the Wnt/ -catenin signalling pathway in human lung cancer cell line A549, inhibiting the expression of proteins such as -catenin and p-GSK3 (Ser9), as well as downstream cyclin D1 and c-Myc. Curcumin bulk powders also down-regulates Notch and HIF-1 mRNA levels, inhibits the expression of VEGF and nuclear factor-κB (NF-κB), and reduces the weight and size of tumours through angiogenic regulation mediated by the vascular endothelial growth factor (VEGF) signalling pathway. Curcumin inhibits cell proliferation, increases apoptosis and G2/M blockade, which is cytotoxic to non-small cell lung cancer, and också inducerar produktion av reaktiva syrearter (ROS), som aktiverar DNA -skador signalvägar .}
När det gäller samadministrering kan kombinationen av curcumin och gemcitabin öka känsligheten för multidrug-resistenta cellinjen A549/GEM till gemcitabin och avsevärt minska migrationen och invasiva förmågan hos A549/GEM-celler .Bulkcurcuminpulvercan also inhibit the expression of DNA methylation-associated enzymes in NSCLC cells, increase the cytotoxicity of crizotinib through the modulation of miR-142-5p and its target Ulk1,and induce tumour It can increase the cytotoxicity of Crizotinib by regulating miR-142-5p and its target Ulk1, and induce apoptosis of tumour Celler .
• Anti-bröst cancereffekter
Akt/mTOR-dependent pathway is a major signalling pathway for breast cancer cell proliferation, and clinical evidence suggests that targeting this pathway is a promising therapeutic option. Curcumin bulk powders inhibits the phosphorylation of Akt, mTOR and their downstream proteins, leading to cell cycle arrest in a variety of breast cancer cell lines, including T47D and MCF 7. NF-kB spelar en nyckelroll i spridningen, invasionen och metastasen av bröstcancercellinjer . bulk curcuminpulver har visat lovande resultat i bekämpning av läkemedelsresistens som är gemensamma för olika tumörer, inklusive bröstcancer .}
Nya studier har visat att belastning av curcumin- och paclitaxel -nanogelleveranssystem kan uppnå den synergistiska effekten av de två läkemedlen, bättre hämmar spridningen av MCF -7 bröstcancerceller och förbättrar behandlingens effektivitet medan de minskade de negativa effekterna i bröstcancerbehandling .}}
• Anti-kolon- och gastriska cancereffekter
Kaskadreaktionen orsakad av PI3K/Akt/mTOR, Wnt/-cateni, NF -KB och andra signalvägar är alla viktiga faktorer i utvecklingen av gastrisk cancer .Bulkcurcuminpulverhas shown good anti-tumour effects by inhibiting p53, Ras, extracellular signal-regulated kinase (ERK), PI3K/Akt multiple signalling pathways in gastric cancer cells. In recent years thymidylate synthase (TS) has been investigated as a major target for anticancer drugs. correlation of TS expression with E2F-1 levels has been identified as a tumour characteristic of human colon cancer. nF-κB inhibitors inhibit cell cycle progression and down-regulate E2F-1. curcumin derivatives, based on natural products, have been used as non-toxic dietary supplements and as herbal medicines.
• Anti-prostatcancereffekter
In vitro-studier har identifierat curcumin som ett effektivt medel vid behandling av prostatacancer . 95 curcuminpulver stör flera molekylära signalvägar såsom NF-KB, mitogen-aktiverat proteinkinas (MAPK) och epidermal tillväxtfaktor (EGFR) .}}}}}Bulkcurcuminpulverinhiberade uttrycket av steroidogena akuta reglerande proteiner såsom HSD3B2 och CYP11A1 in vitro och nedreglerade uttrycket av AR i lymfkörtelkarcinom i prostata (LNCAP) cellinjer .
Guanjie Biotech -erbjudandenburcuminpulverthat appears as yellow powder. Our product is analyzed using the High-Performance Liquid Chromatography (HPLC) method. We are capable of conducting tests in our laboratory, or we can supply third-party testing reports. For further inquiries, please contact us atinfo@gybiotech.com.
Referenser:
1．Mardaneh P, LaVian S, Bagherniya M, Roufogalis B, Sahebkar A . Syntetiska curcuminanaloger i behandlingen av cancer: en litteraturöversikt . curr Med Chem . 2024 Jan 23. Doi: 10 . 2174/0109298673256932231123151626. Epub före tryck. PMID: 38265396.
2. Zhang Qi, He Longxi, Zheng Xin, Zhang Jian . Forskningsframsteg på antitumoureffekten av curcumin [J] . West China Journal of Pharmacy, 2023,38 (04):473-476.}
3. Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, DE Lillo A, Laino L, Lo Muzio L. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med. 2015 Nov; 10 (5): 1615-1623. doi: 10.3892/ETM .2015.2749. Epub 2015 sep 17. PMID: 26640527; PMCID: PMC 4665301.
4. Mimeault M, Batra SK. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med. 2011 Aug 23;6:31. doi: 10.1186/1749-8546-6-31. PMID: 21859497; PMCID: PMC 3177878.
5. Nocito MC, De Luca A, Prestia F, Avena P, La Padula D, Zavaglia L, Sirianni R, Casaburi I, Puoci F, Chimento A, Pezzi V. Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability. Biomediciner . 2021 14 oktober; 9 (10): 1476. doi: 10.3390/biomedicin 9101476. PMID: 34680593; PMCID: PMC 8533288.
6. Panda AK, Chakraborty D, Sarkar I, Khan T, Sa G. New insights into therapeutic activity and anticancer properties of curcumin. J Exp Pharmacol. 2017 Mar 31;9:31-45. doi: 10 . 2147/jep.s 70568. PMID: 28435333; PMCID: PMC 5386596.
